Enveric Biosciences (ENVB) vs Kyntra Bio (KYNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kyntra Bio is the larger company by market cap ($6.3 million vs $6.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENVB | KYNB |
|---|---|---|
| Share price | $1.35 | $1.56 |
| Market cap | $6.04M | $6.32M |
| 1-day change | -4.26% | -13.33% |
| YTD return | — | -82.23% |
| 1-year return | — | -81.47% |
| 5-year return | — | -99.49% |
| EPS (TTM) | $-13.01 | $-4.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.44M |
| Revenue growth (YoY) | — | -78.26% |
| Net income (latest FY) | $-8.77M | $183.45M |
| Gross margin | — | 91.37% |
| Operating margin | — | -712.66% |
| Net margin | — | 2848.63% |
| 52-week high | $13.25 | $10.47 |
| 52-week low | $1.17 | $1.56 |
| Distance from 52-week high | -89.81% | -85.10% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2442.95% |
| Average volume | 56.55K | 29.96K |
| Shares outstanding | 4.48M | 4.05M |
| Employees | 5 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enveric Biosciences
ENVB stock →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
ENVB vs KYNB FAQ
Which is bigger, Enveric Biosciences or Kyntra Bio?
Kyntra Bio (KYNB) is larger, with a market capitalization of $6.32M compared with $6.04M for Enveric Biosciences (ENVB).
Are Enveric Biosciences and Kyntra Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.